TrialArthritis and rheumatism2013

Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.

James R O'Dell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.